论文部分内容阅读
DNA启动子异常甲基化在原发性肝细胞癌(HCC)中是早期、普遍事件。启动子异常甲基化作为一种表观遗传学改变,与HCC的发生、发展及预后密切相关。HCC患者血浆和癌组织中基因甲基化水平具有良好的一致性,血浆是研究甲基化的可靠资源。检测HCC患者血浆DNA启动子异常甲基化对HCC的早期诊断、病情和疗效观察、预后评估具有一定的应用价值。
Aberrant methylation of the DNA promoter is an early, common event in primary hepatocellular carcinoma (HCC). Promoter abnormal methylation as an epigenetic change, and the occurrence, development and prognosis of HCC are closely related. HCC patients with plasma and cancer tissue methylation levels have good consistency, plasma is a reliable source of methylation. Detection of abnormal DNA methylation in plasma of HCC patients may have some value in the early diagnosis of HCC, the observation of disease status, curative effect and prognosis.